AstraZeneca PLC (LON:0A4J)

Market Cap	177.02B
Revenue (ttm)	43.19B
Net Income (ttm)	5.62B
Shares Out	n/a
EPS (ttm)	3.59
PE Ratio	31.50
Forward PE	n/a
Dividend	1.20 (1.60%)
Ex-Dividend Date	Feb 21, 2025

Volume	465
Average Volume	9,560
Open	74.53
Previous Close	77.39
Day's Range	74.53 - 74.90
52-Week Range	60.48 - 87.62
Beta	0.16
RSI	68.65
Earnings Date	Apr 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4J

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD